title: Clinical and angiographic results with the NIR stent: First International NIR Endovascular Stent Study (FINESS-II).
abstract: BACKGROUND: Although safety and efficacy of the NIR trade mark stent have been reported, the long-term angiographic and clinical outcomes have yet to be investigated. The FINESS-II study (First International NIR Endovascular Stent Study) was designed to assess the procedural safety of single 9 and 16 mm NIR stent implantation, the six-month restenosis rate and finally the six- and 12-month clinical outcome of patients treated with this novel coronary stent. METHODS: Patients with angina and a single de novo lesion in a native coronary artery of >3 and <5 mm diameter were included in this multicentre, prospective, observational trial. Clinical follow-up was obtained at one, six and 12 months. Angiography was performed before and after the stent implantation and at six months. The primary endpoint included major adverse cardiac events (death, myocardial infarction and target lesion revascularization) within 30 days after the procedure. Major bleeding complications and subacute stent thrombosis within the first 30 days were also reported as specific endpoints. Secondary endpoints were major cardiac-event-free survival at six- and 12-month follow-up and angiographic restenosis at six months. RESULTS: A total of 156 patients (81% male, mean age 60 +/- 10 years), with stable (54%), unstable (40%) angina pectoris or silent ischemia (6%) were enrolled. The target vessel diameter was 2.94 +/- 0.54 mm. The minimal lumen diameter pre, post and at follow-up was 1.04 +/- 0.32 mm, 2.64 +/- 0.42 mm and 1.88 +/- 0.63 mm, respectively. Restenosis rate according to the >50% diameter stenosis criterion at six month follow-up was 19% (26/136). At 12 months, the event-free survival rate was 83% (two deaths, one Q-wave and three non-Q-wave myocardial infarctions, four bypass surgery and 17 target lesion revascularizations), while 87% of the patients were free of angina pectoris. CONCLUSION: the outcome of the FINESS-II trial is comparable to those observed in previous stent trials (Benestent II), indicating that the coronary NIR stent is safe and effective as a primary device for the treatment of native coronary artery lesions in patients with (un)stable angina pectoris.
authors.affiliation: Universitätsklinikum Charité, Berlin, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Rutsch
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Kiemeneij
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Carlos
authors.initials: C
authors.lastname: Macaya
authors.forename: Jean-Leon
authors.initials: JL
authors.lastname: Guermonprez
authors.forename: Lars
authors.initials: L
authors.lastname: Grip
authors.forename: Jaap
authors.initials: J
authors.lastname: Hamburger
authors.forename: Victor
authors.initials: V
authors.lastname: Umans
authors.forename: Mervyn
authors.initials: M
authors.lastname: Gotsman
authors.forename: Yaron
authors.initials: Y
authors.lastname: Almagor
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Morice
authors.forename: Eulogio
authors.initials: E
authors.lastname: Garcia
authors.forename: Bernard
authors.initials: B
authors.lastname: Chevalier
authors.forename: Raimund
authors.initials: R
authors.lastname: Erbel
authors.forename: Michael
authors.initials: M
authors.lastname: Cobaugh
authors.forename: Marie-Angèle
authors.initials: MA
authors.lastname: Morel
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys